Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$216.27 -0.6%	$201.39	$163.81 ▼ $221.76	$384.42B	0.53	4.30 million shs	4.25 million shs
AMGN Amgen	$273.08 -0.5%	$291.69	$253.30 ▼ $339.17	$147.73B	0.49	1.89 million shs	2.16 million shs
GILD Gilead Sciences	$110.86 -1.5%	$114.05	$81.83 ▼ $121.83	$139.64B	0.36	5.80 million shs	5.46 million shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	86 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.76%	+2.76%	+4.66%	+16.74%	+10.47%
AMGN Amgen	-0.48%	-2.46%	-7.89%	-5.71%	-18.55%
GILD Gilead Sciences	-1.49%	-4.23%	-6.34%	+2.65%	+33.31%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$216.27 -0.6%	$201.39	$163.81 ▼ $221.76	$384.42B	0.53	4.30 million shs	4.25 million shs
AMGN Amgen	$273.08 -0.5%	$291.69	$253.30 ▼ $339.17	$147.73B	0.49	1.89 million shs	2.16 million shs
GILD Gilead Sciences	$110.86 -1.5%	$114.05	$81.83 ▼ $121.83	$139.64B	0.36	5.80 million shs	5.46 million shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	86 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.76%	+2.76%	+4.66%	+16.74%	+10.47%
AMGN Amgen	-0.48%	-2.46%	-7.89%	-5.71%	-18.55%
GILD Gilead Sciences	-1.49%	-4.23%	-6.34%	+2.65%	+33.31%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$220.43	1.92% Upside
AMGN Amgen	2.24	Hold	$304.43	11.48% Upside
GILD Gilead Sciences	2.89	Moderate Buy	$116.04	4.68% Upside
SGEN Seagen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ABBV, AMGN, GILD, and SGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2025	ABBV AbbVie	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$200.00 ➝ $235.00
9/16/2025	GILD Gilead Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$135.00 ➝ $145.00
9/15/2025	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$215.00 ➝ $245.00
9/12/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$240.00 ➝ $260.00
9/12/2025	ABBV AbbVie	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$215.00 ➝ $240.00
9/5/2025	GILD Gilead Sciences	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Moderate Buy
9/3/2025	AMGN Amgen	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform
8/25/2025	ABBV AbbVie	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/25/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$328.00 ➝ $342.00
8/19/2025	GILD Gilead Sciences	Daiwa America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/19/2025	GILD Gilead Sciences	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$128.00

(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.78	$14.84 per share	14.57	$1.90 per share	113.83
AMGN Amgen	$33.42B	4.40	$30.24 per share	9.03	$10.93 per share	24.98
GILD Gilead Sciences	$28.75B	4.78	$6.77 per share	16.38	$15.44 per share	7.18
SGEN Seagen	$2.30B	18.66	N/A	N/A	$15.10 per share	15.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	102.99	15.47	1.40	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
AMGN Amgen	$4.09B	$12.23	22.33	12.77	2.38	18.96%	174.71%	13.12%	10/29/2025 (Estimated)
GILD Gilead Sciences	$480M	$5.02	22.08	13.67	0.76	21.86%	50.99%	17.24%	11/5/2025 (Estimated)
SGEN Seagen	-$610.31M	-$4.01	N/A	N/A	N/A	-32.61%	-28.06%	-20.92%	N/A

Latest ABBV, AMGN, GILD, and SGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.96	$2.01	+$0.05	$1.55	$6.95 billion	$7.08 billion
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.03%	N/A	312.38%	53 Years
AMGN Amgen	$9.52	3.49%	N/A	77.84%	14 Years
GILD Gilead Sciences	$3.16	2.85%	N/A	62.95%	10 Years
SGEN Seagen	N/A	N/A	N/A	N/A	N/A

Latest ABBV, AMGN, GILD, and SGEN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/5/2025	ABBV AbbVie	quarterly	$1.64	3.08%	10/15/2025	10/15/2025	11/14/2025
7/29/2025	GILD Gilead Sciences	quarterly	$0.79	2.81%	9/15/2025	9/15/2025	9/29/2025
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
AMGN Amgen	7.24	1.31	0.98
GILD Gilead Sciences	1.13	1.32	1.15
SGEN Seagen	N/A	2.67	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
SGEN Seagen	84.26%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
AMGN Amgen	0.69%
GILD Gilead Sciences	0.27%
SGEN Seagen	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.77 billion	Optionable
AMGN Amgen	28,000	538.36 million	534.65 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
SGEN Seagen	3,256	187.70 million	139.08 million	Optionable

ABBV, AMGN, GILD, and SGEN Headlines

Recent News About These Companies

Trial win sets up new use for Astellas, Seagen's Padcev in bladder cancer

March 15, 2025 | pharmaphorum.comP

Merck in "advanced talks" for $40bn Seagen bid; report

March 7, 2025 | pharmaphorum.comP

Seagen posts breast cancer win ahead of Pfizer takeover

February 23, 2025 | pharmaphorum.comP

Is Merck planning a $30bn-plus move for Seagen?

December 6, 2024 | pharmaphorum.comP

Pfizer raises guidance as COVID franchise drives Q3 beat

October 30, 2024 | seekingalpha.com

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

October 30, 2024 | seekingalpha.com

Franklin Biotechnology Discovery C

October 5, 2024 | morningstar.comM

Seagen wins Enhertu patent dispute with Daiichi Sankyo

July 19, 2024 | pharmaphorum.comP

Pfizer: Turning The Corner (Rating Upgrade)

May 27, 2024 | seekingalpha.com

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

April 13, 2024 | wsj.com

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

April 2, 2024 | pharmaphorum.comP

Ron Baron Portfolio Magic: Building Your Financial Future

March 20, 2024 | msn.com

Bailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving markets

March 13, 2024 | msn.com

Pfizer shutting down Seagen's $350M construction project in Everett

March 1, 2024 | bizjournals.com

Neuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk Says

February 24, 2024 | finance.yahoo.com

MRNA Feb 2024 64.000 put

February 23, 2024 | finance.yahoo.com

MRNA Feb 2024 77.000 call

February 23, 2024 | finance.yahoo.com

Pfizer adds bull at Guggenheim on ex-COVID prospects

February 23, 2024 | msn.com

MRNA Feb 2024 67.000 put

February 22, 2024 | finance.yahoo.com

Pfizer touts cancer efforts in first Super Bowl commercial

February 12, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABBV, AMGN, GILD, and SGEN Company Descriptions

AbbVie NYSE:ABBV

$216.27 -1.34 (-0.62%)

Closing price 09/16/2025 03:59 PM Eastern

Extended Trading

$215.89 -0.38 (-0.18%)

As of 09/16/2025 07:53 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Amgen NASDAQ:AMGN

$273.08 -1.32 (-0.48%)

Closing price 09/16/2025 04:00 PM Eastern

Extended Trading

$273.60 +0.53 (+0.19%)

As of 09/16/2025 07:52 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$110.86 -1.68 (-1.49%)

Closing price 09/16/2025 04:00 PM Eastern

Extended Trading

$111.01 +0.15 (+0.14%)

As of 09/16/2025 07:55 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABBV, AMGN, GILD, and SGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABBV, AMGN, GILD, and SGEN Earnings

Compare Dividends

Latest ABBV, AMGN, GILD, and SGEN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABBV, AMGN, GILD, and SGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABBV, AMGN, GILD, and SGEN Company Descriptions

AbbVie NYSE:ABBV

Amgen NASDAQ:AMGN

Gilead Sciences NASDAQ:GILD

Seagen NASDAQ:SGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools